Regonix 40MG ( Regorafenib )
Product Name: Regonix ( Regorafenib )
Generic Name: Regorafenib
Formulation: Tablet
Available Pack Size: 28’s
Available Strengths: 40mg
Registrations: Bangladesh
Product Information
Regonix (Regorafenib) 40mg is an oral multikinase inhibitor used to treat metastatic colorectal cancer (mCRC), gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma (HCC) in patients who have progressed on prior standard therapies. It works by inhibiting multiple membrane-bound and intracellular kinases involved in tumour angiogenesis, oncogenesis, and the tumour microenvironment, cutting off the blood supply and growth signals that solid tumours depend on. Manufactured by Beacon Pharmaceuticals PLC, Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Regonix (Regorafenib) 40mg
| Brand Name | Regonix (Regorafenib) |
| Generic Name | Regorafenib INN |
| Drug Class | Oral Multikinase Inhibitor (Angiogenic, Stromal and Oncogenic Kinase Inhibitor) |
| Available Strength | 40mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 28 Tablets per Bottle |
| Primary Indication | Metastatic Colorectal Cancer, Gastrointestinal Stromal Tumour, and Hepatocellular Carcinoma |
| Regulatory Approvals | USFDA Approved (mCRC, GIST, HCC). EMA Approved. |
| Originator Brand | Stivarga by Bayer |
| Manufacturer | Beacon Pharmaceuticals PLC, Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered with the Directorate General of Drug Administration (DGDA), Bangladesh |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Regonix (Regorafenib) Works
Regonix contains Regorafenib, a small-molecule inhibitor of multiple membrane-bound and intracellular kinases involved in both normal cellular function and pathological processes such as oncogenesis, tumour angiogenesis, metastasis, and tumour immunity. Solid tumours rely on these signalling pathways to grow new blood vessels, evade the immune system, and spread to other tissues.
Regorafenib inhibits a broad range of receptor tyrosine kinases, including VEGFR1, VEGFR2, and VEGFR3, TIE2, KIT, PDGFR-alpha and PDGFR-beta, RET, FGFR1 and FGFR2, RAF-1, BRAF (including the BRAF V600E mutant), and CSF1R. By simultaneously blocking angiogenic, stromal, and oncogenic signalling, Regonix cuts off the blood supply tumours need to grow, disrupts the supportive tumour microenvironment, and slows the proliferation and spread of cancer cells.
Because of this broad, multi-target mechanism, Regonix is typically used after other standard treatments, including chemotherapy or other targeted agents, have been tried and are no longer effective. It is administered as a once-daily oral tablet in a cyclical dosing schedule.
Indications for Regonix (Regorafenib)
Regonix (Regorafenib) is indicated for the following conditions:
|
Metastatic Colorectal Cancer (mCRC) For adult patients previously treated with fluoropyrimidine-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. |
Gastrointestinal Stromal Tumour (GIST) For adult patients with locally advanced, unresectable, or metastatic GIST previously treated with imatinib and sunitinib. |
|
Hepatocellular Carcinoma (HCC) For adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. |
|
Benefits of Regonix (Regorafenib) 40mg
|
Broad Multi-Tumour Coverage Approved across three distinct cancer types, colorectal cancer, GIST, and hepatocellular carcinoma, Regonix offers a later-line option when other standard treatments have stopped working. |
Broad Multikinase Action By targeting angiogenic, stromal, and oncogenic kinases simultaneously, Regonix addresses multiple tumour survival pathways at once, rather than a single target. |
Convenient Oral Dosing As an oral tablet taken on a cyclical schedule, Regonix allows patients to continue treatment on an outpatient basis rather than requiring hospital-based infusions. |
|
Affordable Alternative to Stivarga Regonix contains the same active ingredient as Stivarga by Bayer, at a significantly lower cost, making later-line targeted therapy more financially accessible to patients worldwide. |
Dose-Adjustable Regimen Treatment can be interrupted and reduced in defined steps to manage side effects, allowing many patients to continue therapy at a tolerated dose rather than stopping altogether. |
WHO-GMP and cGMP Certified Produced by Beacon Pharmaceuticals PLC under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards, ensuring every batch of Regonix meets consistent quality, safety, and efficacy requirements. |
How to Take Regonix (Regorafenib)
Route: Oral, taken by mouth. Tablets should be swallowed whole with water.
Standard dose: 160mg (four 40mg tablets) once daily, taken for the first 21 days of each 28-day cycle, followed by a 7-day break, and repeated for as long as clinical benefit continues, exactly as directed by the prescribing oncologist.
With food: Take at the same time each day with a low-fat meal (for example, containing less than 30% fat). Avoid high-fat meals, which significantly increase drug absorption and may increase the risk of side effects.
Missed dose: If a dose is missed, do not take it if less than 12 hours remain before the next scheduled dose. Do not double up doses.
Dose reduction for toxicity: For most Grade 3 or 4 adverse reactions (other than hepatotoxicity or infection), treatment is interrupted and, upon recovery, resumed at a reduced dose of 120mg (three tablets) once daily. If toxicity recurs, a further reduction to 80mg (two tablets) once daily may be considered. Treatment is generally discontinued if 80mg once daily cannot be tolerated.
Hepatic impairment: No dose adjustment is required in mild to moderate hepatic impairment. Regonix is not recommended in severe hepatic impairment due to a lack of safety data.
Renal impairment: No dose adjustment is generally required in mild to moderate renal impairment. Use in severe renal impairment or end-stage renal disease has not been well studied.
CYP3A4 interactions: Avoid coadministration with strong CYP3A4 inhibitors and inducers where possible, as these significantly alter Regorafenib exposure.
Paediatric use: The safety and efficacy of Regonix in children and adolescents have not been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Regonix treatment. Your oncologist will check liver function tests before starting treatment, at least every 2 weeks during the first 2 months, and periodically thereafter. Monitoring also includes blood pressure, checked weekly for at least the first 6 weeks, signs of bleeding, wound healing before and after any surgical procedure, and skin examinations for hand-foot skin reaction and severe rash. Report any yellowing of the skin or eyes, dark urine, unusual bleeding or bruising, severe headache, chest pain, or signs of infection to your doctor immediately.
Drug Interactions and Important Information
Avoid concomitant use of Regonix with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, and ritonavir) and strong CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin), as these significantly alter Regorafenib plasma exposure. Use with caution alongside warfarin and other anticoagulants, monitoring INR frequently, as Regonix may increase bleeding risk.
Monitor closely for increased exposure when combined with BCRP substrate medications. Surgery or invasive procedures should be planned around Regonix treatment, as it may impair wound healing; treatment is typically interrupted before elective surgery. Women of childbearing potential should use effective contraception during treatment and for a period after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Regonix.
Side Effects and Precautions
|
Common Side Effects Fatigue and asthenia Diarrhoea Hand-foot skin reaction and rash Decreased appetite and weight loss Hypertension Mucositis and mouth soreness Nausea and abdominal pain Hoarse voice (dysphonia) and fever |
Serious Warnings and Precautions Severe and sometimes fatal hepatotoxicity. Requires regular liver function monitoring. Severe or life-threatening haemorrhage. Gastrointestinal perforation or fistula. Discontinue permanently if this occurs. Cardiac ischaemia and infarction. Reversible posterior leukoencephalopathy syndrome (RPLS), a rare neurological condition. Impaired wound healing. Interrupt treatment before planned surgery. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Regonix (Regorafenib)?
Regonix is suitable for adult patients with metastatic colorectal cancer who have already received fluoropyrimidine-based chemotherapy, anti-VEGF therapy, and, where appropriate, anti-EGFR therapy; adult patients with gastrointestinal stromal tumours previously treated with imatinib and sunitinib; and adult patients with hepatocellular carcinoma previously treated with sorafenib. It is prescribed by medical oncologists experienced in managing later-line, multi-kinase inhibitor therapy. A thorough medical assessment including liver function, blood pressure, and bleeding risk is required before initiating treatment.
Manufacturer: Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. Regonix is registered with the Directorate General of Drug Administration (DGDA) of Bangladesh, and Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards, offering an affordable and bioequivalent alternative to Stivarga at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Regonix (Regorafenib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Regonix (Regorafenib) from Mediaid Pharmacy?
Regonix represents an important later-line option for patients whose colorectal cancer, GIST, or liver cancer has progressed on prior standard therapy. As the generic equivalent of Stivarga by Bayer, it delivers the same active ingredient, Regorafenib, with the same proven multikinase inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals PLC under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Regonix gives patients worldwide access to advanced targeted cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Regorafenib option with worldwide delivery, Regonix from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Regonix (Regorafenib)
What is Regonix (Regorafenib) used for?
Regonix (Regorafenib) is an oral multikinase inhibitor used to treat adult patients with metastatic colorectal cancer, gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma (liver cancer) who have already been treated with standard prior therapies such as chemotherapy, imatinib/sunitinib, or sorafenib. It works by blocking multiple signalling pathways tumours rely on to grow and spread.
How should I take Regonix (Regorafenib)?
Regonix is taken orally, once daily, with a low-fat meal, for the first 21 days of each 28-day cycle, followed by a 7-day break. The standard dose is 160mg (four 40mg tablets) once daily. Dose reductions to 120mg or 80mg once daily may be used to manage side effects. Always follow your oncologist’s exact instructions.
What strength is Regonix (Regorafenib) available in?
Regonix is available in a 40mg film-coated tablet, supplied in a bottle of 28 tablets. Because Regonix is available in the 40mg strength, the standard 160mg dose is achieved by taking four tablets together once daily, exactly as prescribed by your oncologist.
Is Regonix the same as Stivarga (Regorafenib by Bayer)?
Yes. Regonix is the generic equivalent of Stivarga. Both contain the same active ingredient, Regorafenib, and work through the same multikinase inhibition mechanism. Regonix is manufactured by Beacon Pharmaceuticals PLC in Bangladesh and offers the same clinical mechanism as Stivarga at a significantly lower cost.
What are the side effects of Regonix (Regorafenib)?
Common side effects include fatigue, diarrhoea, hand-foot skin reaction, decreased appetite, and high blood pressure. Regonix carries a boxed warning for severe and sometimes fatal liver injury, and also carries risks of severe bleeding, gastrointestinal perforation, and cardiac events. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.
Can Regonix be used with other medications?
Regonix should not be combined with strong CYP3A4 inhibitors or inducers without a physician-directed dose adjustment. Use caution with warfarin and other anticoagulants due to increased bleeding risk, and treatment is usually paused before planned surgery due to effects on wound healing. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Regonix.
Is Regonix (Regorafenib) safe during pregnancy or breastfeeding?
No. Regonix is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential should use effective contraception during treatment and for a period after the final dose, as advised by their physician. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Regonix (Regorafenib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Regonix (Regorafenib) 40mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Regonix (Regorafenib) 40mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
